A-54
Simultaneous screening and confirmation of multi-class antibiotic residues in shrimp by a LC-MSn method
H. Li, W. Cui, P. J. Kijak, FDA
The indiscriminate use of antibiotics in shrimp aquaculture can lead to illegal drug residues in shrimp sold to US consumers. The abuse of antibiotics in shrimp production may cause health, environmental, and drug-resistance problems. As most shrimp consumed in the US is imported, the FDA needs methods to screen for illegal drug residues to protect US consumers. A multi-class, multi-residue LC-tandem-MS method has been developed to quickly screen and confirm a wide variety of antibiotic residues in shrimp Presently, 18 compounds, representing 6 classes of drugs, i.e., tetracyclines, sulfonamides, quinolones, fluoroquinolones, (leuco)dyes, and triazine-triones, are included in the screening procedure. They are either unapproved or banned by US FDA for use in shrimp aquaculture. An extraction with 5% trichloroacetic acid, followed by SPE clean-up, provides clean sample extracts for analysis. Ion-trap mass spectrometry provides highly specific and sensitive monitoring for the residues. The target concentrations for method validation are 200 ng/g for oxytetracycline (one tenth current action level), 100 ng/g for toltrazuril sulfone, 25 ng/g for sulfaquinoxaline, and 10 ng/g or lower for the other 15 drugs. Method validation was conducted using both fortified and incurred shrimp, and several commonly raised shrimp species. Combined with a quantitative method to be developed in a future project, FDA will have a wide spectrum, high throughput method to detect illegal drug residues in shrimp.
2004 FDA Science Forum | FDA Chapter, Sigma Xi | CFSAN | FDA
Last updated on 2004-APR-02 by frf